Kodiak Sciences Inc KOD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
-
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
-
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Trading Information
- Previous Close Price
- $40.87
- Day Range
- $41.24–43.45
- 52-Week Range
- $5.00–47.84
- Bid/Ask
- $40.50 / $45.00
- Shares Outstanding
- 62.58M
- Market Cap
- $2.65B
- Volume/Avg
- 452,798 / 717,884
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 124
- Website
- https://www.kodiak.com
Valuation
|
Metric
|
KOD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 23.64 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KOD
|
|---|---|
Quick Ratio | 3.42 |
Current Ratio | 3.54 |
Interest Coverage | — |
Quick Ratio
KOD
Profitability
|
Metric
|
KOD
|
|---|---|
Return on Assets (Normalized) | −61.37% |
Return on Equity (Normalized) | −185.83% |
Return on Invested Capital (Normalized) | −115.07% |
Return on Assets
KOD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!Qg^sg! | LOCK|%?#k% | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|m!^<!d | LOCK|&RC< | $71B | |||
| argenx SE ADR
ARGX
| LOCK|@Sn!Gr | LOCK|^y | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&vR$&c | LOCK|<?^ | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?DDgv#Y | LOCK|?>$FF | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<Cmc<^? | LOCK|#!R&f | $26B | |||
| Moderna Inc
MRNA
| LOCK|&Hn&SV | LOCK|&%Z | $24B | |||
| Incyte Corp
INCY
| LOCK|h@#ryLc | LOCK|%!s | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Wm@<<@ | LOCK|tdY | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|lT@RY? | LOCK|@Qf | $16B |
United States